Claims for Patent: 9,662,360

Summary for Patent: 9,662,360

Title:	Treatment of herpes, pseudomonas, staph, and hepatitis
Abstract:	An improved method (process) is provided to treat herpes, pseudomonas, staphylococcus (staph), and hepatitis and help treat or alleviate cold sores, rashes, skin conditions, or symptoms resulting from herpes, pseudomonas, staph, and hepatitis. The method uses a special medicinal composition which can be self-administered and maintained for a prescribed time. The attractive medicinal composition can comprise a quaternary ammonium salt surfactant, a skin protectant and an alcohol. The quaternary ammonium salt surfactant can comprise benzalkonium halide, preferably benzalkonium chloride. The skin protectant can comprise Allantoin. The alcohol can serve as a pain reliever and can comprise benzyl alcohol. The medicinal composition can also include other compounds, additives, herbal extracts and/or carriers. Desirably, the medicinal composition is maintained on the infected regions until external symptoms and physical manifestations of the symptoms resulting from herpes, pseudomonas, hepatitis, or staph substantially disappear from the infected regions.
Inventor(s):	Squires; Meryl J. (Barrington, IL)
Assignee:	Meritus Corporation (DM)
Application Number:	14/961,035
Patent Claims:	1. A process to treat herpes and to help treat or alleviate cold sores, rashes, skin conditions, or symptoms resulting from herpes, comprising: providing an anti-herpes medicinal composition comprising by weight based on the total weight of the anti-herpes medicinal composition: substantially greater than 0.01% to about 0.8% by weight aqueous or dry benzalkonium chloride; from about 0.01% to about 99% Allantoin; at least 10% to about 99% benzyl alcohol; said benzalkonium chloride, Allantoin and benzyl alcohol being present in the medicinal composition in the absence of Myrtle and/or Centaurea and their extracts, as well as Echinacea angustofolia, aedurid, sodium hydroxide (Na OH); tea tree oil, lapacho extract, licorice root extract, arabinose, betaine, cellulose, copper, fructose, fatty acids, galactose, glucose, iron, potassium, protein, resin, sucrose, and xylose; Echinacea purpurea selected from the group consisting of extracts of Echinacea purpurea, portions of Echinacea purpurea, and combinations thereof; said anti-herpes medicinal composition comprises a coating selected from the group consisting of a powder, gel, ointment, and paste; said herpes selected from the group consisting of herpes simplex virus 1 (HSV 1), herpes simplex virus 2 (HSV 2), varicella zoster virus (herpes zoster) (shingles), cytomegalovirus, herpetic keratitis, conjunctivitis, human immunedeficiency virus infection (HIV), viral influenza (flu), esptein barr; papilloma virus, viral parainfluenza, adenovirus, viral encephalitis, viral meningitis, arbovirus, arenavirus, picornavirus, coronavirus, syntialvirus, viral infections, roseola infantum, pneumonia, mononucleosis, uveitis, retinitis, human cervical carcinoma, vaginal carcinoma, vulvovaginitis, human herpes IV, Kaposi's sarcoma, cytomegalovirus, and common colds; and applying said anti-herpes medicinal composition to herpes or to cold sores, rashes, skin conditions, or symptoms resulting from herpes to treat herpes and help treat or alleviate the cold sores, rashes, skin conditions, or symptoms resulting from herpes. 2. A process in accordance with claim 1 wherein the anti-herpes medicinal composition is applied on an external portion of an animal selected from the group consisting of a dog, cat, bird, horse, cow, sheep, swine, farm animal and rodent. 3. A process in accordance with claim 1 wherein: the anti-herpes medicinal composition is applied topically to the cold sores, rashes, skin conditions, or infected regions by a procedure selected from the group consisting of spraying, dabbing, dusting, swabbing, sponging brushing, pouring, dispensing, covering and coating; and the infected regions are selected from the group consisting of lips, mouths, oral mucosa, nasal mucosa, vaginal tissue, labial tissue, anal tissue, periacinal tissue, cutaneous tissue, ocular tissue, conjunctive, and eye lids. 4. A process in accordance with claim 1 wherein external symptoms and physical manifestations of the symptoms of cold sores substantially disappear in about one day or less after the anti-herpes medicinal composition is applied to the cold sores. 5. A process in accordance with claim 1 wherein external symptoms and physical manifestations of the symptoms of vesicular eruption, rash, or skin conditions resulting from herpes simplex virus are substantially resolved in about 19 hours to about 24 hours after the composition is applied to the vesicular eruption, rash or skin condition. 6. A process in accordance with claim 1 for topical treatment of active phase lesions resulting from herpes, further comprising the steps of: conditioning and treating an active phase herpes lesion on skin or mucosa ting from herpes of a person (human being) (homo sapien) by sequentially moistening and powdering said active phase herpes lesion; and said moistening comprising wetting the active phase lesion on skin or mucosa with an aqueous solution of said anti-herpes medicinal composition in the absence of Myrtle and/or Centaurea and their extracts, as well as Echinacea angustofolia, aedurid, sodium hydroxide (Na OH), tea tree oil, lapacho extract, licorice root extract, arabinose, betaine, cellulose, copper, fructose, fatty acids, galactose, glucose, iron, potassium, protein, resin, sucrose, and xylose. 7. A process in accordance with claim 1, further comprising: substantially resolving the physical symptoms of an infected area of a person having an infectious outbreak of herpes or other infectious disease within about 1 hour to about 30 hours by topically applying the anti-herpes medicinal composition to the infected area of said herpes or said other infectious disease; and maintaining the anti-herpes medicinal composition on said infected area for about 1 hours to about 30 hours. 8. A process to treat pseudomonas and help treat or alleviate rashes, skin conditions, or symptoms resulting from pseudomonas, comprising: providing an anti-pseudomonas medicinal composition comprising the following by weight based on the total weight of the anti-pseudomonas medicinal composition: from about 0.02% to 0.3% by weight aqueous or dry benzalkonium chloride; from about 0.05% to about 30% Allantoin; from 10% to about 30% benzyl alcohol; sterile water; methyl cellulose; methyl paraben; potassium sorbate; propyl paraben; and the ratio of said sterile water to said benzalkonium chloride in said medicinal composition ranges from about 30,000:1 to about 250:1; said anti-pseudomonas medicinal composition comprising a coating selected from the group consisting of a powder, gel, ointment and paste; and applying said anti-pseudomonas medicinal composition to pseudomonas or to rashes, skin conditions, or symptom resulting from pseudomonas to treat pseudomonas and help treat or alleviate the rashes, skin conditions, or symptoms resulting from pseudomonas. 9. A process in accordance with claim 8, further comprising: substantially inhibiting symptoms resulting from pseudomonas by applying the anti-pseudomonas medicinal composition on the regions infected by pseudomonas; and maintaining the anti-pseudomonas medicinal composition on the regions infected from pseudomonas until external symptoms and physical manifestations of the symptoms resulting from pseudomonas substantially disappear from the infected regions. 10. A process to treat hepatitis and help treat or alleviate symptoms resulting from hepatitis, comprising: providing an anti-hepatitis medicinal composition comprising the following weight based on the total weight of the anti-hepatitis medicinal composition: from about 0.02% to 0.3% by weight aqueous or dry benzalkonium chloride; from about 0.05% to about 30% Allantoin; from 10% to about 30% benzyl alcohol; sterile water; methyl cellulose; methyl paraben; potassium sorbate; propyl paraben; the ratio of said sterile water to said benzalkonium chloride in said medicinal composition ranges from about 30,000:1 to about 250:1; said hepatitis is selected from the group consisting of hepatitis B and hepatitis C; and applying said anti-hepatitis medicinal composition to hepatitis or to symptoms resulting, from hepatitis to treat hepatitis and help treat or alleviate symptoms resulting from hepatitis. 11. A process in accordance with claim 10 further comprising: substantially inhibiting symptoms resulting from hepatitis by applying the anti-hepatitis medicinal composition on the regions infected by hepatitis; and maintaining the anti-hepatitis medicinal composition on the regions infected from hepatitis until external symptoms and physical manifestations of the symptoms resulting from hepatitis substantially disappear from the infected regions. 12. A process to treat staph (staphylococcus) and help treat or alleviate rashes, skin conditions, or other symptoms resulting from staph, comprising: providing an anti-staph medicinal composition, comprising the following by weight based on the total weight of the anti-staph medicinal composition: from about 0.02% to 0.3% by weight aqueous or dry benzalkonium chloride; from about 0.05% to about 30% Allantoin; from 10% to about 30% benzyl alcohol; sterile water; methyl cellulose; methyl paraben; potassium sorbate; propyl paraben; said anti-staph medicinal composition comprises a coating selected from the group consisting of a powder, gel, ointment, and paste; the ratio of said sterile water to said benzalkonium chloride in said medicinal composition ranges from about 5000:1 to about 750:1; and applying said anti-staph medicinal composition to staph or to rashes, skin conditions or other symptoms resulting from staph to treat staph and help treat or alleviate rashes, skin conditions, or other symptoms resulting from staph. 13. A process in accordance with claim 12 further comprising: substantially inhibiting symptoms resulting from staph by applying the anti-staph medicinal composition on the regions infected by staph; and maintaining the anti-staph medicinal composition on the regions infected from staph until external symptoms and physical manifestations of symptoms resulting from staph substantially disappear from the infected regions.

Details for Patent 9,662,360

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2028-10-09